Mizuho announced Allergan plc Ordinary Shares (NYSE:AGN), boosting its stock price target to $318.00 today
- Updated: September 17, 2016
Showing a price of $253.54, Allergan plc Ordinary Shares (NYSE:AGN) traded 0.51% lower on the day. With the last stock price up 0.18% relative to the 200-day moving average, compared with the S&P 500 Index which has fallen -0.01% over the date range. The company has been tracking to a 50-day moving average of $247.03 and 200-day moving average of $244.75. Volume of trade was was up over the average, with 3,358,894 shares of AGN changing hands over the typical 3,000,800 shares.
Mizuho upped the price target of Allergan plc Ordinary Shares (NYSE:AGN) to $318, reporting a possible upside of 0.25%,
On 8/19/2016, Mizuho Securities released a statement on Allergan plc Ordinary Shares(NYSE:AGN) bumped the target price from $248.00 to $318.00 that indicated a possible upside of 0.26%.
Recent Performance Chart:
A total of 16 analysts have reported on the stock. Seven analysts rate the stock a strong buy, 11 firms rate the company a buy, two firms rate the company a hold, 0 rate the stock to underperform, and lastly 0 brokeragesrate the company as sell with an average target price of $293.75
With a market cap of $0.0, Allergan plc Ordinary Shares has a PE of 23 with a one-year low of $195.50 and a one-year high of $322.68.
Brief Synopsis About Allergan plc Ordinary Shares (NYSE:AGN)
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, and medical aesthetics, as well as dermatology and plastic surgery. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. Allergan plc also distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physiciansÂ’ offices. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, and Ireland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.